US5320094A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Method of administering insulin
Assignee: Johns Hopkins University
•
Filing: 1992-01-10
•
Granted: 1994-06-14
•
Expires: 2012-01-10
Abstract
Abstract A method of delivering a protein, in particular insulin, to the lungs. The method is characterized in that an aerosolized mist of small particles is produced in an associated medicament delivery chamber, the distance from the chamber to the patient's mouth is set to slow the speed of aerosol particles entering the mouth and the flow rate through the chamber is regulated to a low rate of less than about 30 liters per minute. It has been found that administering insulin in accordance with the invention may advantageously produce a penetration of medication into the lungs of about 90%.
Inventors
- 👤 Beth L. Laube
- 👤 G. Kenneth Adams, III
- 👤 Angeliki Georgopoulos
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-09 02:38
CPC Classifications
A; A61; A61M; A61M15/00; A61M15/0086; A61M15/0088; A61M15/0001; A61M15/002; A61M15/009
Claims Analysis
Total Claims: 4
Claim 1
Independent Claim
180 words
A method for delivering insulin for absorption via the lungs of a patient, comprising the steps of: determining a therapeutically effective amount of said insulin, consistent with the body weight and condition of the patient; determining an effective number of inhalations required by a patient for inspiration of said therapeutically effective amount of insulin; providing an inhaler device having a chamber for receiving aerosolized insulin to be inhaled and means for selectively restricting gas flow into said chamber; providing aerosolized insulin at a regulated inspiratory flow rate of below 30 liters/minute; delivering a mean dose of aerosolized insulin comprising said therapeutically effective amount of insulin to the patient for inspiration; inhaling said mean does of aerosolized insulin from said inhaler device at said regulated inspiratory flow rate, said regulated inspiratory flow being selected to maximize the amount of aerosolized insulin deposited for absorption via the lungs into the bloodstream of the patient, whereby a therapeutically effective amount of said insulin, consistent with the body weight and condition of the patient, is inhaled and absorbed into the bloodstream of the patient.
Claim 2
Independent Claim
180 words
A method for delivering insulin for absorption via the lungs of a patient, comprising the steps of: determining a therapeutically effective amount of said insulin, consistent with the body weight and condition of the patient; determining an effective number of inhalations required by a patient for inspiration of said therapeutically effective amount of insulin; providing an inhaler device having a chamber for receiving aerosolized insulin to be inhaled and means for selectively restricting gas flow into said chamber; providing aerosolized insulin at a regulated inspiratory flow rate of below 30 liters/minute; delivering a mean dose of aerosolized insulin comprising said therapeutically effective amount of insulin to the patient for inspiration; inhaling said mean does of aerosolized insulin from said inhaler device at said regulated inspiratory flow rate, said regulated inspiratory flow being selected to maximize the amount of aerosolized insulin deposited for absorption via the lungs into the bloodstream of the patient, whereby a therapeutically effective amount of said insulin, consistent with the body weight and condition of the patient, is inhaled and absorbed into the bloodstream of the patient.
Claim 3
Dependent Claim
12 words
The method of claim 1, wherein said flow rate is 17 liters/min.
Claim 4
Dependent Claim
24 words
The method of claim 1, wherein the patient's mouth is positioned in fluid communication with the chamber at a present distance from the chamber.
References Cited (Backward Citations)
FR933216A
Cited
US2944546A
Cited
US2788784A
Cited
US4119097A
Cited
US4484577A
Cited
GB2110543A
Cited
US4612929A
Cited
US4534343A
Cited
US4624251A
Cited
US4635627A
Cited
US4677975A
Cited
US4829996A
Cited
US4790305A
Cited
US4796614A
Cited
SU1524904A1
Cited
US4929852A
Cited
US5027806A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1997-06-13 | 1997-12-13 | 1998-06-14 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 2001-06-13 | 2001-12-13 | 2002-06-14 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2005-06-13 | 2005-12-13 | 2006-06-14 | $7700.00 | Window Closed / Lapsed |